Colorectal cancer isn't an 'old person's disease,' advocates warn. A stage 4 cancer survivor shares 5 things you should never do if you want to avoid the disease
Colorectal cancer is a serious health risk for many Canadians — including people under age 50. More than 25,200 people were diagnosed with colorectal cancer in 2024, making it the fourth most commonly diagnosed cancer in Canada last year. Now, advocates want all provinces and territories to lower the screening age for the disease to 45.
"Our objective is to ensure that young Canadians do not ignore the signs and symptoms just because of their age and that they are aware of their family medical history and risk level, as we call on our provincial and territorial health ministries to lower the screening age for colorectal cancer throughout the country to 45," Barry Stein, president and CEO of Colorectal Cancer Canada, explains in a press release on Tuesday.
This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Contact a qualified medical professional before engaging in any physical activity, or making any changes to your diet, medication or lifestyle.
The non-profit adds that colorectal cancer might be perceived as an "old person's disease," but shares that early-onset colorectal cancer is on the rise and that cancer doesn't care about your age. Most new cases still occur in people age 50 and above, but Canadians born after 1980 are two to two-and-a-half times more likely to be diagnosed with colorectal cancer before age 50 compared to earlier generations.
According Colorectal Cancer Canada, 26 people die from the illness everyday on average, with around 69 people receiving a diagnosis daily. For 2024, it was estimated that 9,400 Canadians died from colorectal cancer, making up 11 per cent of all cancer deaths last year.
Colorectal cancer cancer grows more slowly than some other cancer and can stay in the colon or rectum for months or even years. If left untreated, it can spread to other parts of the body, but if found early, colorectal cancer can often be cured. This is why Stein points out that colorectal cancer can be preventable through lifestyle choices, awareness of symptoms and early screening.
In 1995, while juggling the demands of his legal career, Stein began noticing various concerning symptoms. Those included blood in his stool, migraines, abdominal pain and nausea, which he dismissed as related to stress.
"I was turning 41 at the time and had no idea what cancer even was," Stein recalls in a previous interview with Yahoo Canada. "People didn't say that word so much in 1995, let alone colorectal cancer. These were symptoms that came and went, so I ignored them."
It wasn't until he finally had a fecal occult blood test and colonoscopies that the diagnosis hit: Stage IV colorectal cancer, which had spread to his liver and lungs.
Still, Stein stresses a person's health doesn't have to get to this point; he shares five things Canadians should and shouldn't do to help prevent colorectal cancer.
Unexplained changes in bowel habits, blood in the stool, persistent abdominal pain, unexplained weight loss or fatigue should never be symptoms you ignore.
These signs might also be linked to other gastrointestinal conditions, including ulcers, Crohn's disease or hemorrhoids, according to the Colorectal Cancer Canada website. That means "just because you have these symptoms doesn't mean you have colon cancer," Stein adds.
"But they are a reason to be checked out."
Regular screenings are important because colorectal cancer often develops from precancerous polyps, or growths in the colon or rectum. Catching and removing these polyps early can prevent them from becoming cancerous.
Starting at age 50, you should undergo routine fecal occult blood tests and colonoscopies. Even though everybody has the right to get screened starting at age 50, the Canadian Partnership Against Cancer states the "screening participation rate across the country is still below the national target of 60 per cent."
Despite this, Colorectal Cancer Canada highlights that the screening guidelines have effectively reduced cancer rates in those over age 50, demonstrating their life-saving potential.
However, there is a rise in cases among younger adults, particularly those with a family history of colorectal cancer, Stein notes. These individuals are often diagnosed at a later stage because they are not getting screened and health-care professionals may not suspect cancer at a young age.
If you're under 50 and experiencing related symptoms, or have a family history of colorectal cancer or polyps, you may need to start screening early. "Speak to your doctor about your personal testing plan," the organization advises.
The Foods That Fight Cancer program by Colorectal Cancer Canada recommends eating a diet rich in whole grains, fruits and vegetables. These foods are high in fibre, which helps keep the digestive system healthy and can lower the risk of colorectal cancer.
In addition to these foods, the program advises limiting the intake of processed meats and red meat, which are associated with a higher risk of colorectal cancer. It also recommends reducing the amount of alcohol and sugary beverages you drink. Highly processed foods should be minimized as well.
By making these dietary changes, the risk of developing colorectal cancer can be minimized, Stein points out.
Incorporate regular exercise into your routine, as physical inactivity is a significant risk factor for colorectal cancer. Stein highlights, "Having a sedentary lifestyle, in other words, being a couch potato, is a risk factor."
Staying active not only helps maintain a healthy weight but also reduces the risk of colorectal cancer. According to Colorectal Cancer Canada, regular physical activity can lower the risk by improving bowel function and reducing inflammation.
Discuss your family history of colorectal cancer with a health-care provider so you understand the risk. If you have a first-degree relative — such as a parent, sibling or child — who's had colorectal cancer, your risk is higher. Shared genetics and lifestyle factors contribute to this increased risk, according to Colorectal Cancer Canada.
Moreover, genetic syndromes like Lynch syndrome (hereditary nonpolyposis colorectal cancer) can elevate your risk further. People with Lynch syndrome are more likely to develop colorectal cancer, often at a younger age. Other inherited conditions, like familial adenomatous polyposis (FAP), which causes numerous polyps in the colon and rectum, also heighten the risk.
"Your age and generic history of your family are risk factors that you can't control," Stein says, adding the goal is to focus on what can be controlled, like eating healthier foods and exercising.
Prevention is often more straightforward than treatment, which can be invasive and challenging. As Stein states, "it's so much easier to prevent something (than to treat it)."
"All you have to do is get a kit, poop in your toilet, send it to the lab with a little stick and you find out if it's positive," Stein explains.
If it does turn out positive, you would then go for a colonoscopy so that the polyp can be located.
"If there is a polyp, they remove it and you catch the cancer early. Otherwise, you go through what I went through, which is quite challenging, to say the least. And at worst, people die."
By focusing on early screening and prevention, potential issues can be caught early before developing into cancer, ultimately saving lives and reducing the burden of treatment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
AKC pet insurance review 2025
AKC pet insurance rating: 1.7 out of 5 stars AKC pet insurance can be an attractive option if your pet has preexisting conditions: After 365 days of continuous coverage with AKC, the preexisting conditions can be covered. With other pet insurance companies, preexisting conditions are permanently excluded. But AKC's rating in our evaluation was hampered by a lack of robust coverage in the base policy – you have to buy a number of add-ons if you want to build generous coverage. In fact, AKC pet insurance was the only policy in our evaluation that does not cover hereditary and congenital conditions in the base policy – that requires a rider for extra cost. And average costs were high for the base plan without even factoring in extra costs for riders. Learn more: How does pet insurance work? A complete guide. Pros Wide range of deductible choices from $100 to $1,000 Covers alternative therapies such as acupuncture and chiropractic care Breeding coverage available Covers emergency ground pet ambulance transportation in emergencies Cons High average cost Highest annual coverage choice of $10,000 unless you choose the Basic plan with a $500 lifetime limit Add-ons required if you want coverage for vet exam fees, hereditary and congenital conditions, behavioral therapy, and more AKC pet insurance basics Annual maximum limit choices: $2,500, $5,000, $7,500, $10,000 for a custom plan; unlimited option available with a limit of $500 per injury or illness over the lifetime of the pet Deductible choices: $100-$1,000 in increments Reimbursement choices: 70%, 80%, 90% AKC waiting periods For accident coverage: 2 days For illness coverage: 14 days Special waiting period: 180 days for cruciate ligament issues AKC age restrictions for buying a new policy Minimum pet age: None (in most states) Maximum pet age: None AKC offers an accident and illness policy, an accident-only policy, and a pet wellness plan. AKC's accident and illness base policy includes coverage for: X-rays, ultrasounds, and other diagnostics Surgery and hospitalization Dental accidents Chemotherapy, hydrotherapy, and physical therapy Alternative therapies Prescription drugs Pet ambulance transportation Prescription pet food if it is the sole treatment for a condition Euthanasia Learn more: Your guide to what pet insurance covers Add-ons to AKC's accident and illness policy Expect to pay more if you want this extra coverage: ExamPlus to cover vet exam fees HereditaryPlus to cover hereditary and congenital conditions and chronic conditions like arthritis, and diabetes SupportPlus for certain end-of-life expenses BreedingCoverage for medical expenses related to breeding, pregnancy and whelping, nursing, and emergency c-sections The accident-only plan from AKC covers X-rays, lab tests, medication, surgery, hospitalization, and more when there's an accidental injury. This includes problems such as a broken bone, bite wound, cut, or bee sting. AKC offers two wellness plan options: Defender and DefenderPlus. Both cover routine care costs, with the more expensive DefenderPlus option providing higher reimbursement levels for treatments. Defender: Coverage for up to $305 of wellness benefits costs $17/month, $204/year DefenderPlus: Coverage for up to $535 of wellness benefits costs $29/month, $348/year The Defender and DefenderPlus plans will reimburse you up to specified limits for the following: Wellness exam Vaccinations and titer testing Rabies Flea and tick prevention Heartworm prevention Screening for heartworm and feline leukemia Blood, fecal, parasite exam Deworming Urinalysis or ERD Microchipping DefenderPlus also covers spaying, neutering, and dental cleaning. Learn more: Does pet insurance cover vaccines? Yes, AKC will cover preexisting conditions after 365 days of continuous coverage. A preexisting condition is defined as an illness or injury that occurred, reoccurred, existed, or showed symptoms prior to the start date of coverage or during the waiting period. Learn more: Pet insurance that covers preexisting conditions Yes, AKC provides access to a 24/7 vet helpline. The service's licensed veterinarians can answer general questions and offer advice on when to seek medical care for your pet, but they can't diagnose or provide treatment. AKC pet insurance does not cover expenses such as: Anal gland expression Boarding and transportation (including non-emergency ambulance) Conditions due to racing, organized fighting, and security/law enforcement training Congenital and inherited conditions (unless you purchase add-on coverage) Cremation and burial (unless you purchase add-on coverage) Dental care (unless you purchase add-on coverage) Elective cosmetic procedures Experimental treatments Grooming Illness or injury from intentional acts Illness or injury from war, riots, pandemics and avian or swine flu More than one injury from repetitive behavior, such as swallowing objects Pet food Preventive care (unless you purchase add-on coverage) Weight and obesity treatment, if not due to a medical condition AKC does not specify whether you can increase or decrease your coverage. You must contact the company if you want to make a change to your coverage. Changes are subject to underwriting and AKC's approval. Some changes might result in new enrollment, which would reset your waiting period and the 365-day waiting period for treatment of preexisting conditions. AKC pet insurance costs were very high compared to many competitors in our evaluation. The cost of AKC pet insurance was 22% higher than the over all average in our analysis of policies with a $5,000 annual limit. Yes, AKC offers a 5% discount if you insure more than one pet. However, the multi-pet discount isn't available in all states. Most pet insurance companies' multi-pet discounts are 5% or 10%. No, you must pay your vet and file a claim to be reimbursed. However, if you expect a large bill, contact AKC ahead of time to ask if it will make a special arrangement to pay your vet directly. Learn more: Pet insurance that pays the vet directly Here's what to know about filing claims with AKC: To file a claim: Submit an AKC reimbursement claim form and an itemized invoice from your vet through the online customer portal or by email, mail, or fax. To submit claims quickly: Use the online customer portal to submit documents electronically. To receive reimbursements faster: Opt to have reimbursements directly deposited into your checking or savings account. If a claim is denied: You have the right to appeal. You must file claims within 180 days of the date of treatment or receipt of an invoice. If you submit a claim by email or through your online account, you should receive an immediate notification that your claim was received, according to AKC. You'll receive a notification within one business day after a mailed or faxed claim is received. Once claims are received, they are assigned to a claims agent within two business days, then payment is typically made within one day if all required documents have been submitted. Payment for claims requiring additional documentation can take up to 30 days. AKC uses the Pet Cloud app, which is also shared by Figo pet insurance and others. The app allows you to quickly submit claims, store your policy documents and pet's medical records, and get 24/7 access to a vet to ask questions. It can also send you reminders about vet appointments, help you connect with pet owners in your area, and find pet-friendly places and services. AKC mobile app ratings: App store: 4.8 out of 5 stars Google Play store: 3.8 out of 5 stars Learn more: The best pet insurance companies AKC pet insurance is available in all 50 states and the District of Columbia. AKC doesn't specify whether it requires an exam for coverage. You can contact AKC by phone, email, fax or mail: Contact AKC at 866-725-2747 from 8 a.m. to 8 p.m. ET Monday through Friday and from 8:30 a.m. to 5 p.m. ET on Saturday The email address is help@ The fax number is 919-859-8193 The mailing address is AKC Pet Insurance c/o PetPartners, P.O. Box 2150, Buffalo, NY 14240-2150 You can cancel a policy at any time by calling 866-725-2747. You can receive a full refund of your premium if you cancel within 30 days and haven't filed any claims. If you cancel after 30 days, the amount of your refund will be calculated on a daily pro rata basis. Tim Manni edited this article. We researched the coverage details and prices for 15 pet insurance plans. We then weighted categories, and each pet insurer was scored relative to the others to find the best pet insurance companies. Here are the factors we incorporated. Coverage types: 40% of score. We examined the coverage provided by the base policy without the extra cost of add-ons. This encompassed coverage for alternative therapy, behavioral therapy, dental illness, euthanasia or end-of-life expenses, exotic pets, hereditary and congenital conditions, preexisting conditions, prescription food and supplements, veterinary exam fees, and advertising/reward for lost/stolen pets. Average cost: 30% of score. We evaluated costs in five states for $5,000 and unlimited coverage for a mixed-breed dog (age 1), a French bulldog (age 5), and a Labrador retriever (age 8). Unlimited coverage option: 10% of score. We gave points when pet insurers offered an unlimited annual limit (or a $100,000 limit), which gives pet owners the most robust financial protection possible in the event of a catastrophic pet medical issue. Direct payments to the veterinarian: 5% of score. We gave points to pet insurers that state on their websites that they accommodate direct vet payments. No special waiting periods for special conditions: 5% of score. We gave points when pet insurers have no waiting periods for special conditions, such as cruciate ligament conditions. Routine wellness plan: 5% of score. Companies that offer a routine wellness plan in addition to pet insurance received points. Multi-pet discount: 5% of score. We gave points when pet insurers offered a discount for insuring multiple pets.
Yahoo
3 hours ago
- Yahoo
UnitedHealth's Rebound: Hidden Strength or Hiding Weakness?
Recently, UnitedHealth Group (UNH, Financial) has been the subject of many headlines because of DOJ probes, kickback accusations in nursing homes, and a shocking departure of its CEO. In addition, the value of its shares has dropped by almost 50%. Yet, underneath the news, the business is still strong. Health insurance remains important and strong throughout economic downturns and doesn't react to changes in global trade. In the aftermath, a clear development can be noticed as Stephen Hemsley was appointed CEO again and bought a large amount of stock which fueled a quick increase in share prices. Warning! GuruFocus has detected 4 Warning Sign with UNH. This is real conviction. UnitedHealth is focusing more on Medicaid-managed care, widening value-based care with Optum, and looking into growing its business in dual-eligible and long-term care. The company's financials confirm the trend since earnings have quadrupled in ten years, cash flow is strong, and insiders are buying in. In short, UnitedHealth is using the uncertainty to its advantage. Long-term investors may find the current price as an attractive chance to enter a company that has shown lasting and solid growth. UnitedHealth Group is the biggest health insurer in the United States and ranks highly internationally in healthcare. Its two key segments, UnitedHealthcare and Optum, give people health benefits, pharmacy services, data analysis, and healthcare. More than 150 million people are helped by this company, which is continuing to expand by combining operations and offering value-based care. The company provides insurance through commercial, Medicare, and Medicaid markets, and Optum sparks new ideas in care coordination and pharmaceutical services. UnitedHealth is smartly diversified. The company is doing well due to managed care growth, making money from healthcare improvements, and strategically serving top segments thanks to Optum doing the main work. Medicaid managed care expansion capturing state-level shifts: The move of Medicaid recipients from fee-for-service to managed care can bring huge benefits to UnitedHealth. According to industry statistics, UNH and four other large insurers cover over 50% of people in Medicaid-managed care across the nation. So, when several hundred thousand to millions switch plans, it has a huge effect on the company's finances. Since monthly premiums for complex patients in these states are $600$800, New York, Pennsylvania, and Michigan could add hundreds of millions of dollars to their annual premium earnings. Because of its connections with states, UNH is in a good position to win a major share of this revenue. Value-based care & optum scale turning outcomes into profit: Optum, which drives UNH's value-based approach, recorded $253 billion in revenue in 2024, which was 12% higher than the previous year, and $16.7 billion in operating income. Currently, Optum Health works with close to 4.7 million people in value-based contracts and plans to add another 650k in 2025. Focus on patient care and cost savings are the main aims of these models, and UNH supports this. When Optum grows its care coordination and home services, shared-savings revenue plays a bigger role, already bringing in hundreds of millions and capable of much more. High-Value segments target the dual-eligible and long-term care markets: Instead of raising its volume, UNH is focusing on high-paying customer groups, such as those with both Medicare and Medicaid and patients needing long-term care. Dual-eligibles may receive $2,500 monthly, which means each person will get $30,000 annually. Currently, UNH serves about 500k people, but if it could capture just 2 million of the national enrollments, it could earn $45 billion in annual premiums. Vertical integration with optum: Thanks to Optum, UNH has all its services combined, including pharmacy (over 1.62 billion scripts were handled by OptumRx in 2024), care delivery, data analysis, and provider management. Because of this integration, UNH is ahead in long-term care, managing care effectively, reducing expenses, and boosting results, which other organizations don't have. Overall, UnitedHealth is a leader that is making steady earnings now and is prepared to capture the future of healthcare and population wellness. Now, let's investigate the financial side of UnitedHealth Group. The company had good first-quarter earnings, but it sent a cautious message for the coming months. UnitedHealth Group's quarterly revenue of $109.6 billion was $10 billion higher than the same period last year, showing how much both UnitedHealthcare and Optum are growing. While adjusted EPS of $7.20 surpassed $6.91 from the earlier period, the company adjusted its full-year forecast down to expect adjusted EPS of $26.00 to $26.50. So, what leads to this change of tone? While UnitedHealthcare welcomed 780,000 new members, increased use of health services in Medicare Advantage by its customers caused the company's medical costs to increase above expectations. Because more people needed outpatient and physician care, the medical care ratio rose to 84.8%. For healthcare delivery, this is not necessarily an issue, yet it can still hurt business if prices fall short. Meanwhile, Optum Health experienced challenges with a more diverse member group and reduced payments due to less involvement among members in 2024. Even so, Optum achieved a $63.9 billion revenue thanks to its Rx division, which filled 408 million adjusted scripts. UNH is also operating efficiently, with its operating cost ratio now 12.4%, free cash flow at $5.5 billion, and a high 26.8% return on equity. The company also gave $5 billion back to its shareholders. All in all, UNH's basics are solid, but it has to deal with some short-term problems first. UnitedHealth Group has consistently improved its earnings over the years. In the year 2015, diluted earnings per share was only $6.01. Looking at the trailing twelve months, the number has reached $23.88. Over the past decade, the amount has almost quadrupled. It is even more impressive that the growth has been steady over the years. For many years, UnitedHealth kept increasing its profits, demonstrating the power of its varied businesses and strict management. The only major drop in EPS happened in 2024, with the figure reaching $15.51. Although this was an unusual dip in the company's history, it is on track for a solid recovery in 2025, and first-quarter adjusted EPS was $7.20. Looking into the future, analysts believe the trend will not stop. Even though 2025 is, in some ways, a year of recovery with a projected EPS of $22.59, the company's growth kicks in afterward. By 2026, analysts predict EPS will increase to $26.40, and then keep growing at double-digit rates, aiming for $45.83 by 2030. Source: Author generated based on historical data All in all, despite some occasional setbacks, UnitedHealth's future growth is steady, so patient investors are still in a position to be rewarded. The increase in EPS matches the upward trend in revenue per share. It highlights the company's steady growth and increased success. In the year 2015, the company's revenue per share was $162.47. Now, that figure is $443.16 TTM. That's a 170% jump in ten years, which clearly shows the company is making better use of its growth to help shareholders. What's most promising is that this growth keeps happening consistently. Revenue per share has increased year after year and stayed strong through different economic conditions and impacts on the industry. It is a result of the company attracting more members and expanding its main businesses, UnitedHealthcare and Optum. Once more, this trend keeps happening in the future. Revenue forecasts keep going up from $449.81 billion in 2025 to more than $591 billion by 2030. Minor changes in growth do not stop the company from expanding and creating more value for its shareholders. Source: Author generated based on historical data UnitedHealth Group's free cash flow per share is a reliable sign of how well the company is financially and operationally. The amount of free cash flow per share in 2015 was $8.46. Afterward, the company increased this number, reaching $26.82 for the TTM, which is more than three times higher than its value a decade back. What stands out about this growth is that it follows closely in line with the company's earnings trajectory. Therefore, we see that UnitedHealth's profits are being turned into cash that can be used to strengthen the business, cut debt, or be given back to its shareholders. Being that efficient is not common in an industry that relies heavily on capital like healthcare. UnitedHealth Group gives investors a good dividend since the dividend yield is 2.92% and the payout ratio is only 30%, which suggests that dividends could increase in the future. It's worth noting that over the past 5 years, the company has seen a 14.6% growth in its dividend, which tops inflation and profits long-term investors. Through ten years of constant raises, the yield on cost increases to 15.38%. Although UNH is offering a high yield now, low buybacks mean most capital is shared through dividends. UnitedHealth Group looks deeply undervalued right now. According to GuruFocus, the stock is trading about half its worth, as the fair value is $633.16 but it is currently trading at $303.22. There is a massive disconnect here, and it's very unusual for a company as stable as UNH to deviate so much from its fair value estimate. Valuation multiples are also telling the same story. The forward P/E of this stock is 13.42, which is much lower than the average of 17.66, giving a discount of 23.98%. The company's forward EV/EBITDA of 9.61 is better than the sector's ratio of 11.79. On a price-to-sales ratio, UNH is trading at 0.61 times its projected sales, while the healthcare industry is pricing in at 3.43xa discount of 82%. All in all, UNH gives you both quality and value. Almost all of the valuation measures suggest that the company is undervalued in terms of its earnings, sales, and cash flow. Even though the stock is built on solid foundations and pays out more in dividends each year, it still trades at a lower price than its competitors. As a result, long-term investors can take advantage of acquiring a leader in healthcare at a much lower price than its actual value. When measured against companies like Humana (HUM, Financial) and HealthEquity (HQY, Financial), UnitedHealth Group is still a good buy. Because its forward P/E is lower than HUM's 14.1 times and much lower than HQY's 30 times, it attracts those who want to invest for growth as well as value. Considering price-to-sales, UNH trades at 0.68 times, making it more valuable than HQY's 7.8 while being slightly higher than HUM's very low 0.23. On the EV/EBITDA ratio, UNH stands at 9.6x forward, quite similar to HUM's 9.2x and much less than HQY's 19.2x. All in all, UNH is well-balanced by giving investors scale, profits, dividend growth, and a reasonably attractive price. HUM also does well in various areas, especially when it comes to managing expenses and the way the company works. But in the long run, investors admire UNH for its consistent results and potential to increase. Source: Author generated based on data Going forward, I feel UnitedHealth Group (NYSE:UNH) is well-positioned to achieve a price target of $395$410 in the next year and possibly surpass $525$550 by 2027. Despite the stock's recent volatility, the numbers, the company's health, and the outlook seem to fit together nicely. Let's begin our discussion with the short term. Despite many years of increasing earnings and a high rate of cash conversion, UNH is only valued at 13.4 times its future earnings when the stock is trading at $303. Healthcare companies, on the other hand, have a forward P/E of about 17.6, and UNH has generally had a forward P/E between 18x and 20x during calm times. If UNH is valued at just 17 times the expected FY2025 EPS of $22.59, the price would come to $384. At 18x, If stability comes back and the new leaders reassure everyone, the stock could increase to $406. The story gets even better as you look further into the future. Analysts are predicting that EPS will rise to $45.83 by 2030, meaning it will be about double the current earnings in just five years. Multiply the earnings by 15, and the share price comes out to $687. But, let's narrow our focus to conservatism, and for 2027, the predicted EPS is about $34.50. At this multiple of 15x, the price comes out to $517if the market recovers, shares could climb to $550 or more due to the 16x or 17x rating. If the DOJ investigation ends well and Hemsley's efforts to cut costs are successful, the company should do well over the next few quarters. We are not just discussing theory here. Since 2015, UNH's free cash flow per share has more than tripled, its revenue per share has nearly tripled too, and it still has some of the top dividend growth rates in healthcare. Such consistency, size, and under-valuation are hard to find in one company. Let's look at how Wall Street views this area. Looking at the chart, analysts foresee that the price of Apple shares might rise by 26.2% to $382.80 in the next 12 months. It is estimated that the cost can fall anywhere from $270 to $677. To conclude, although there may be short-term ups and downs, it looks like disciplined, patient investors will find more favorable long-term conditions. When Andrew Witty suddenly left his CEO post in May because of profit problems and dropped 2025 guidance, UNH shares fell over 12% to their lowest point in five years and wiped out more than $250 billion in market value. As a consequence, the board brought back former CEO Stephen Hemsley (who headed the company from 2006 to 2017). Within only a few days, Hemsley made a big step by buying nearly 86,700 shares worth about $25 million for $288.60 per share. Hemsley, together with the CFO and several directors, voted to keep the company's value high, and shares rose by about 8% the following trading day. What does it imply? It is clear that the management views the falling share price of UNH as a good time to purchase. The fact that Hemsley has invested his money shows how much he believes in the company after all it has achieved. Yet, this is not a case of blind faith: the company is dealing with an ongoing investigation, higher medical costs in Medicare Advantage, and a cyberattack it suffered recently. From a strategic point of view, all this buying in UNH suggests that the company's leaders believe the worst has passed and risks for the stock are low. The guru trading chart has an interesting narrative. Although UnitedHealth's stock has gone down recently, gurus have been buying it more frequently. Many green bars are appearing, both early in 2024 and again later in 2025, showing that some informed investors are looking at the dip as an opportunity to buy instead of a warning sign. This trend can be seen in the investor's stock portfolio. Vanguard is still the biggest shareholder, but it slightly reduced its holdings. I'm also paying attention to Ken Fisher (Trades, Portfolio) , who bought much more, a solid 52%, and Jeremy Grantham (Trades, Portfolio) , who increased his holding by over 7%. Though there is selling and shares are reduced as well, institutions tend to be cautiously upbeat. Even though UnitedHealth's future looks bright, investors should still pay attention to the risks in the near term. The DOJ is currently investigating the business for possible Medicare Advantage fraud, such as upcoding and billing errors, which is a very serious matter that could result in being fined or charged in court. At the same moment, Washington is paying more attention to supervision. Should reforms reduce the inflation of risk scores or Medicare allowance for nurse practitioners, it could affect the profitability of Medicare Advantage. Q1 faced some issues because the higher use of medical services caused the medical loss ratio to increase to around 85%, and Optum is still learning to handle CMS's updated risk model. Because of these pressures, there could be more budget reductions for guidance. However, the bad news appears to be mostly factored into share prices. For careful investors who believe the company will survive, this could present an opportunity to buy long-term. The headlines can be very tempting, but stepping back, it appears that UnitedHealth is still a powerhouse lurking in plain sight. It is the same old stuff but with a different sentiment. The long-term story is still in place with the reinstatement of Stephen Hemsley, a recent insider purchase, and a long history of expertise in Medicaid-managed care and the Optum platform in value-based care. Most of that bad news, including the increases in care costs, and regulatory noise, appears to be reflected in price. Sentiment can change at any minute as long as we hear a resolution to the DOJ investigation, a slowdown in the trend of rising Medicare costs, or upbeat guidance in coming quarters. Any of those may be the spark. In the meantime, the stock is currently trading at one of the most attractive valuations it has seen in years, and the set-up is of the sort long-term investors tend to reflect back on with gratitude. If you are waiting to have a clear picture, you may miss the opportunity. However, to the patient and longer-term investors, this may be one of those times when interceding in soreness results in actual payoff. In other words, this just might be a smart time to lean in and buy the stock. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
UnitedHealth's Rebound: Hidden Strength or Hiding Weakness?
Recently, UnitedHealth Group (UNH, Financial) has been the subject of many headlines because of DOJ probes, kickback accusations in nursing homes, and a shocking departure of its CEO. In addition, the value of its shares has dropped by almost 50%. Yet, underneath the news, the business is still strong. Health insurance remains important and strong throughout economic downturns and doesn't react to changes in global trade. In the aftermath, a clear development can be noticed as Stephen Hemsley was appointed CEO again and bought a large amount of stock which fueled a quick increase in share prices. Warning! GuruFocus has detected 4 Warning Sign with UNH. This is real conviction. UnitedHealth is focusing more on Medicaid-managed care, widening value-based care with Optum, and looking into growing its business in dual-eligible and long-term care. The company's financials confirm the trend since earnings have quadrupled in ten years, cash flow is strong, and insiders are buying in. In short, UnitedHealth is using the uncertainty to its advantage. Long-term investors may find the current price as an attractive chance to enter a company that has shown lasting and solid growth. UnitedHealth Group is the biggest health insurer in the United States and ranks highly internationally in healthcare. Its two key segments, UnitedHealthcare and Optum, give people health benefits, pharmacy services, data analysis, and healthcare. More than 150 million people are helped by this company, which is continuing to expand by combining operations and offering value-based care. The company provides insurance through commercial, Medicare, and Medicaid markets, and Optum sparks new ideas in care coordination and pharmaceutical services. UnitedHealth is smartly diversified. The company is doing well due to managed care growth, making money from healthcare improvements, and strategically serving top segments thanks to Optum doing the main work. Medicaid managed care expansion capturing state-level shifts: The move of Medicaid recipients from fee-for-service to managed care can bring huge benefits to UnitedHealth. According to industry statistics, UNH and four other large insurers cover over 50% of people in Medicaid-managed care across the nation. So, when several hundred thousand to millions switch plans, it has a huge effect on the company's finances. Since monthly premiums for complex patients in these states are $600$800, New York, Pennsylvania, and Michigan could add hundreds of millions of dollars to their annual premium earnings. Because of its connections with states, UNH is in a good position to win a major share of this revenue. Value-based care & optum scale turning outcomes into profit: Optum, which drives UNH's value-based approach, recorded $253 billion in revenue in 2024, which was 12% higher than the previous year, and $16.7 billion in operating income. Currently, Optum Health works with close to 4.7 million people in value-based contracts and plans to add another 650k in 2025. Focus on patient care and cost savings are the main aims of these models, and UNH supports this. When Optum grows its care coordination and home services, shared-savings revenue plays a bigger role, already bringing in hundreds of millions and capable of much more. High-Value segments target the dual-eligible and long-term care markets: Instead of raising its volume, UNH is focusing on high-paying customer groups, such as those with both Medicare and Medicaid and patients needing long-term care. Dual-eligibles may receive $2,500 monthly, which means each person will get $30,000 annually. Currently, UNH serves about 500k people, but if it could capture just 2 million of the national enrollments, it could earn $45 billion in annual premiums. Vertical integration with optum: Thanks to Optum, UNH has all its services combined, including pharmacy (over 1.62 billion scripts were handled by OptumRx in 2024), care delivery, data analysis, and provider management. Because of this integration, UNH is ahead in long-term care, managing care effectively, reducing expenses, and boosting results, which other organizations don't have. Overall, UnitedHealth is a leader that is making steady earnings now and is prepared to capture the future of healthcare and population wellness. Now, let's investigate the financial side of UnitedHealth Group. The company had good first-quarter earnings, but it sent a cautious message for the coming months. UnitedHealth Group's quarterly revenue of $109.6 billion was $10 billion higher than the same period last year, showing how much both UnitedHealthcare and Optum are growing. While adjusted EPS of $7.20 surpassed $6.91 from the earlier period, the company adjusted its full-year forecast down to expect adjusted EPS of $26.00 to $26.50. So, what leads to this change of tone? While UnitedHealthcare welcomed 780,000 new members, increased use of health services in Medicare Advantage by its customers caused the company's medical costs to increase above expectations. Because more people needed outpatient and physician care, the medical care ratio rose to 84.8%. For healthcare delivery, this is not necessarily an issue, yet it can still hurt business if prices fall short. Meanwhile, Optum Health experienced challenges with a more diverse member group and reduced payments due to less involvement among members in 2024. Even so, Optum achieved a $63.9 billion revenue thanks to its Rx division, which filled 408 million adjusted scripts. UNH is also operating efficiently, with its operating cost ratio now 12.4%, free cash flow at $5.5 billion, and a high 26.8% return on equity. The company also gave $5 billion back to its shareholders. All in all, UNH's basics are solid, but it has to deal with some short-term problems first. UnitedHealth Group has consistently improved its earnings over the years. In the year 2015, diluted earnings per share was only $6.01. Looking at the trailing twelve months, the number has reached $23.88. Over the past decade, the amount has almost quadrupled. It is even more impressive that the growth has been steady over the years. For many years, UnitedHealth kept increasing its profits, demonstrating the power of its varied businesses and strict management. The only major drop in EPS happened in 2024, with the figure reaching $15.51. Although this was an unusual dip in the company's history, it is on track for a solid recovery in 2025, and first-quarter adjusted EPS was $7.20. Looking into the future, analysts believe the trend will not stop. Even though 2025 is, in some ways, a year of recovery with a projected EPS of $22.59, the company's growth kicks in afterward. By 2026, analysts predict EPS will increase to $26.40, and then keep growing at double-digit rates, aiming for $45.83 by 2030. Source: Author generated based on historical data All in all, despite some occasional setbacks, UnitedHealth's future growth is steady, so patient investors are still in a position to be rewarded. The increase in EPS matches the upward trend in revenue per share. It highlights the company's steady growth and increased success. In the year 2015, the company's revenue per share was $162.47. Now, that figure is $443.16 TTM. That's a 170% jump in ten years, which clearly shows the company is making better use of its growth to help shareholders. What's most promising is that this growth keeps happening consistently. Revenue per share has increased year after year and stayed strong through different economic conditions and impacts on the industry. It is a result of the company attracting more members and expanding its main businesses, UnitedHealthcare and Optum. Once more, this trend keeps happening in the future. Revenue forecasts keep going up from $449.81 billion in 2025 to more than $591 billion by 2030. Minor changes in growth do not stop the company from expanding and creating more value for its shareholders. Source: Author generated based on historical data UnitedHealth Group's free cash flow per share is a reliable sign of how well the company is financially and operationally. The amount of free cash flow per share in 2015 was $8.46. Afterward, the company increased this number, reaching $26.82 for the TTM, which is more than three times higher than its value a decade back. What stands out about this growth is that it follows closely in line with the company's earnings trajectory. Therefore, we see that UnitedHealth's profits are being turned into cash that can be used to strengthen the business, cut debt, or be given back to its shareholders. Being that efficient is not common in an industry that relies heavily on capital like healthcare. UnitedHealth Group gives investors a good dividend since the dividend yield is 2.92% and the payout ratio is only 30%, which suggests that dividends could increase in the future. It's worth noting that over the past 5 years, the company has seen a 14.6% growth in its dividend, which tops inflation and profits long-term investors. Through ten years of constant raises, the yield on cost increases to 15.38%. Although UNH is offering a high yield now, low buybacks mean most capital is shared through dividends. UnitedHealth Group looks deeply undervalued right now. According to GuruFocus, the stock is trading about half its worth, as the fair value is $633.16 but it is currently trading at $303.22. There is a massive disconnect here, and it's very unusual for a company as stable as UNH to deviate so much from its fair value estimate. Valuation multiples are also telling the same story. The forward P/E of this stock is 13.42, which is much lower than the average of 17.66, giving a discount of 23.98%. The company's forward EV/EBITDA of 9.61 is better than the sector's ratio of 11.79. On a price-to-sales ratio, UNH is trading at 0.61 times its projected sales, while the healthcare industry is pricing in at 3.43xa discount of 82%. All in all, UNH gives you both quality and value. Almost all of the valuation measures suggest that the company is undervalued in terms of its earnings, sales, and cash flow. Even though the stock is built on solid foundations and pays out more in dividends each year, it still trades at a lower price than its competitors. As a result, long-term investors can take advantage of acquiring a leader in healthcare at a much lower price than its actual value. When measured against companies like Humana (HUM, Financial) and HealthEquity (HQY, Financial), UnitedHealth Group is still a good buy. Because its forward P/E is lower than HUM's 14.1 times and much lower than HQY's 30 times, it attracts those who want to invest for growth as well as value. Considering price-to-sales, UNH trades at 0.68 times, making it more valuable than HQY's 7.8 while being slightly higher than HUM's very low 0.23. On the EV/EBITDA ratio, UNH stands at 9.6x forward, quite similar to HUM's 9.2x and much less than HQY's 19.2x. All in all, UNH is well-balanced by giving investors scale, profits, dividend growth, and a reasonably attractive price. HUM also does well in various areas, especially when it comes to managing expenses and the way the company works. But in the long run, investors admire UNH for its consistent results and potential to increase. Source: Author generated based on data Going forward, I feel UnitedHealth Group (NYSE:UNH) is well-positioned to achieve a price target of $395$410 in the next year and possibly surpass $525$550 by 2027. Despite the stock's recent volatility, the numbers, the company's health, and the outlook seem to fit together nicely. Let's begin our discussion with the short term. Despite many years of increasing earnings and a high rate of cash conversion, UNH is only valued at 13.4 times its future earnings when the stock is trading at $303. Healthcare companies, on the other hand, have a forward P/E of about 17.6, and UNH has generally had a forward P/E between 18x and 20x during calm times. If UNH is valued at just 17 times the expected FY2025 EPS of $22.59, the price would come to $384. At 18x, If stability comes back and the new leaders reassure everyone, the stock could increase to $406. The story gets even better as you look further into the future. Analysts are predicting that EPS will rise to $45.83 by 2030, meaning it will be about double the current earnings in just five years. Multiply the earnings by 15, and the share price comes out to $687. But, let's narrow our focus to conservatism, and for 2027, the predicted EPS is about $34.50. At this multiple of 15x, the price comes out to $517if the market recovers, shares could climb to $550 or more due to the 16x or 17x rating. If the DOJ investigation ends well and Hemsley's efforts to cut costs are successful, the company should do well over the next few quarters. We are not just discussing theory here. Since 2015, UNH's free cash flow per share has more than tripled, its revenue per share has nearly tripled too, and it still has some of the top dividend growth rates in healthcare. Such consistency, size, and under-valuation are hard to find in one company. Let's look at how Wall Street views this area. Looking at the chart, analysts foresee that the price of Apple shares might rise by 26.2% to $382.80 in the next 12 months. It is estimated that the cost can fall anywhere from $270 to $677. To conclude, although there may be short-term ups and downs, it looks like disciplined, patient investors will find more favorable long-term conditions. When Andrew Witty suddenly left his CEO post in May because of profit problems and dropped 2025 guidance, UNH shares fell over 12% to their lowest point in five years and wiped out more than $250 billion in market value. As a consequence, the board brought back former CEO Stephen Hemsley (who headed the company from 2006 to 2017). Within only a few days, Hemsley made a big step by buying nearly 86,700 shares worth about $25 million for $288.60 per share. Hemsley, together with the CFO and several directors, voted to keep the company's value high, and shares rose by about 8% the following trading day. What does it imply? It is clear that the management views the falling share price of UNH as a good time to purchase. The fact that Hemsley has invested his money shows how much he believes in the company after all it has achieved. Yet, this is not a case of blind faith: the company is dealing with an ongoing investigation, higher medical costs in Medicare Advantage, and a cyberattack it suffered recently. From a strategic point of view, all this buying in UNH suggests that the company's leaders believe the worst has passed and risks for the stock are low. The guru trading chart has an interesting narrative. Although UnitedHealth's stock has gone down recently, gurus have been buying it more frequently. Many green bars are appearing, both early in 2024 and again later in 2025, showing that some informed investors are looking at the dip as an opportunity to buy instead of a warning sign. This trend can be seen in the investor's stock portfolio. Vanguard is still the biggest shareholder, but it slightly reduced its holdings. I'm also paying attention to Ken Fisher (Trades, Portfolio) , who bought much more, a solid 52%, and Jeremy Grantham (Trades, Portfolio) , who increased his holding by over 7%. Though there is selling and shares are reduced as well, institutions tend to be cautiously upbeat. Even though UnitedHealth's future looks bright, investors should still pay attention to the risks in the near term. The DOJ is currently investigating the business for possible Medicare Advantage fraud, such as upcoding and billing errors, which is a very serious matter that could result in being fined or charged in court. At the same moment, Washington is paying more attention to supervision. Should reforms reduce the inflation of risk scores or Medicare allowance for nurse practitioners, it could affect the profitability of Medicare Advantage. Q1 faced some issues because the higher use of medical services caused the medical loss ratio to increase to around 85%, and Optum is still learning to handle CMS's updated risk model. Because of these pressures, there could be more budget reductions for guidance. However, the bad news appears to be mostly factored into share prices. For careful investors who believe the company will survive, this could present an opportunity to buy long-term. The headlines can be very tempting, but stepping back, it appears that UnitedHealth is still a powerhouse lurking in plain sight. It is the same old stuff but with a different sentiment. The long-term story is still in place with the reinstatement of Stephen Hemsley, a recent insider purchase, and a long history of expertise in Medicaid-managed care and the Optum platform in value-based care. Most of that bad news, including the increases in care costs, and regulatory noise, appears to be reflected in price. Sentiment can change at any minute as long as we hear a resolution to the DOJ investigation, a slowdown in the trend of rising Medicare costs, or upbeat guidance in coming quarters. Any of those may be the spark. In the meantime, the stock is currently trading at one of the most attractive valuations it has seen in years, and the set-up is of the sort long-term investors tend to reflect back on with gratitude. If you are waiting to have a clear picture, you may miss the opportunity. However, to the patient and longer-term investors, this may be one of those times when interceding in soreness results in actual payoff. In other words, this just might be a smart time to lean in and buy the stock. This article first appeared on GuruFocus. Effettua l'accesso per consultare il tuo portafoglio
